Similar companies
Income Statement (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Revenue | 7.93B | 2% |
| Gross Profit | 6.88B | 11% |
| Cost of Revenue | 1.04B | 33.5% |
| Operating expense | 3.92B | 36.4% |
| Net Income | 2.18B | 28.5% |
| EBITDA | 2.33B | 49.1% |
Balance Sheet (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Total Assets | 59B | 0.8% |
| Total Liabilities | 36.4B | 1.8% |
| Total Equity | 22.6B | 5% |
| Shares Outstanding | 1.25B | 0.1% |
Cash Flow (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Cash from operations | 3.33B | 19% |
| Cash from investing | -1.84B | 329.7% |
| Cash from financing | -1.26B | 15.2% |
EPS
Financial Highlights for Gilead Sciences in Q4 '25
Gilead Sciences reported a revenue of 7.93B, which is a 2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 6.88B, marking a 11% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.04B, a -33.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.92B, showing a 36.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 2.18B, showing a -28.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 2.33B, showing a -49.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Gilead Sciences faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
